{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T06:58:28Z","timestamp":1775890708533,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jval.2022.08.003","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T06:36:04Z","timestamp":1665642964000},"page":"204-215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cost-Effectiveness Analysis of Vaccination With Recombinant Zoster Vaccine Among Hematopoietic Cell Transplant Recipients and Persons With Other Immunocompromising Conditions Aged 19 to 49 Years"],"prefix":"10.1016","volume":"26","author":[{"given":"Andrew J.","family":"Leidner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismael R.","family":"Ortega-Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamison","family":"Pike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa A.","family":"Prosser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen L.","family":"Dooling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jval.2022.08.003_bib1","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1525-1497.2005.0150.x","article-title":"The incidence of herpes zoster in a United States administrative database","volume":"20","author":"Insinga","year":"2005","journal-title":"J\u00a0Gen Intern Med"},{"issue":"3","key":"10.1016\/j.jval.2022.08.003_bib2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jval.2022.08.003_bib3","author":"Leidner"},{"issue":"6","key":"10.1016\/j.jval.2022.08.003_bib4","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/M18-2347","article-title":"A\u00a0cost-effectiveness analysis of vaccination for prevention of herpes zoster and related complications: input for national recommendations","volume":"170","author":"Prosser","year":"2019","journal-title":"Ann Intern Med"},{"issue":"33","key":"10.1016\/j.jval.2022.08.003_bib5","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1016\/j.vaccine.2018.07.005","article-title":"Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States","volume":"36","author":"Curran","year":"2018","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.jval.2022.08.003_bib6","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1093\/cid\/ciz1090","article-title":"Herpes zoster risk in immunocompromised adults in the United States: a systematic review","volume":"71","author":"McKay","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.jval.2022.08.003_bib7","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.39670","article-title":"Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.jval.2022.08.003_bib8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/cid\/ciy953","article-title":"The epidemiology of herpes zoster in the United States during the era of varicella and herpes zoster vaccines: changing patterns among older adults","volume":"69","author":"Harpaz","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jval.2022.08.003_bib10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s15010-013-0550-8","article-title":"Incidence of herpes zoster in patients with altered immune function","volume":"42","author":"Chen","year":"2014","journal-title":"Infection"},{"issue":"7","key":"10.1016\/j.jval.2022.08.003_bib11","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1007\/s12325-017-0553-4","article-title":"Duration of antiviral prophylaxis and risk of herpes zoster among patients receiving autologous hematopoietic stem cell transplants: a retrospective, observational study","volume":"34","author":"Zhang","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.jval.2022.08.003_bib12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.antiviral.2017.01.011","article-title":"Antiviral prophylaxis for preventing herpes zoster in hematopoietic stem cell transplant recipients: a systematic review and meta-analysis","volume":"140","author":"Seo","year":"2017","journal-title":"Antiviral Res"},{"issue":"11","key":"10.1016\/j.jval.2022.08.003_bib13","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/infdis\/jit405","article-title":"Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005-2009","volume":"208","author":"Weinmann","year":"2013","journal-title":"J\u00a0Infect Dis"},{"issue":"2","key":"10.1016\/j.jval.2022.08.003_bib14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/cid\/ciy954","article-title":"The epidemiology of herpes zoster in the United States during the era of varicella and herpes zoster vaccines: changing patterns among children","volume":"69","author":"Harpaz","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jval.2022.08.003_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial","volume":"322","author":"Bastidas","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2022.08.003_bib17","author":"Ortega-Sanchez"},{"key":"10.1016\/j.jval.2022.08.003_bib19","author":"Anderson"},{"issue":"3","key":"10.1016\/j.jval.2022.08.003_bib20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","article-title":"Use of recombinant zoster vaccine in immunocompromised adults aged \u226519 years: recommendations of the Advisory Committee on Immunization Practices - United States, 2022","volume":"71","author":"Anderson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"10.1016\/j.jval.2022.08.003_bib22","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/cid\/ciab125","article-title":"Recombinant zoster Vaccine (Shingrix) real-world effectiveness in the first two years post-licensure","volume":"73","author":"Izurieta","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jval.2022.08.003_bib23","unstructured":"Watson Health, IBM(R) MarketScan(R) Research Databases for Health Services Researchers, IBM Corporation. 2019. Accessed 30 April 2021."},{"issue":"6","key":"10.1016\/j.jval.2022.08.003_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020528","article-title":"Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012","volume":"8","author":"Yanni","year":"2018","journal-title":"BMJ Open"},{"issue":"7","key":"10.1016\/j.jval.2022.08.003_bib25","first-page":"1","volume":"68","author":"Arias","year":"2017","journal-title":"United States life tables, 2007. Natl Vital Stat Rep"},{"issue":"7","key":"10.1016\/j.jval.2022.08.003_bib26","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.bbmt.2014.03.006","article-title":"A\u00a0population-based cohort study of late mortality in adult autologous hematopoietic stem cell transplant recipients in Australia","volume":"20","author":"Ashton","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jval.2022.08.003_bib27","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D\u2019Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jval.2022.08.003_bib28","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/0272989X06290497","article-title":"Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores","volume":"26","author":"Hanmer","year":"2006","journal-title":"Med Decis Making"},{"issue":"12","key":"10.1016\/j.jval.2022.08.003_bib29","doi-asserted-by":"crossref","first-page":"960","DOI":"10.7326\/0003-4819-138-12-200306170-00007","article-title":"Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race","volume":"138","author":"Sisk","year":"2003","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.jval.2022.08.003_bib30","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/j.pain.0000000000001718","article-title":"Aggregate health and economic burden of herpes zoster in the United States: illustrative example of a pain condition","volume":"161","author":"Harvey","year":"2020","journal-title":"Pain"},{"issue":"3","key":"10.1016\/j.jval.2022.08.003_bib31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00019053-200826030-00006","article-title":"Community and patient values for preventing herpes zoster","volume":"26","author":"Lieu","year":"2008","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"10.1016\/j.jval.2022.08.003_bib32","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.bbmt.2019.07.036","article-title":"Recombinant zoster vaccine significantly reduces the impact on quality of life caused by herpes zoster in adult autologous hematopoietic stem cell transplant recipients: a randomized placebo-controlled trial (ZOE-HSCT)","volume":"25","author":"Curran","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jval.2022.08.003_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7525-3-17","article-title":"Health-state valuations for pertussis: methods for valuing short-term health states","volume":"3","author":"Lee","year":"2005","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"10.1016\/j.jval.2022.08.003_bib34","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/jamainternmed.2017.7431","article-title":"Cost-effectiveness of the adjuvanted herpes zoster subunit vaccine in older adults","volume":"178","author":"Le","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.jval.2022.08.003_bib35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jval.2010.10.026","article-title":"Valuing health across the lifespan: health state preferences for seasonal influenza illnesses in patients of different ages","volume":"14","author":"Prosser","year":"2011","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.jval.2022.08.003_bib36","first-page":"928","article-title":"Healthcare resource utilization and costs associated with herpes zoster in the US","volume":"19","author":"Johnson","year":"2016","journal-title":"J\u00a0Med Econ"},{"issue":"9","key":"10.1016\/j.jval.2022.08.003_bib37","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4065\/84.9.787","article-title":"Health care utilization and cost burden of herpes zoster in a community population","volume":"84","author":"Yawn","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"36","key":"10.1016\/j.jval.2022.08.003_bib38","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1016\/j.vaccine.2021.07.050","article-title":"Insurance reimbursements for recombinant zoster vaccine in the private sector","volume":"39","author":"Leidner","year":"2022","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.jval.2022.08.003_bib39","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.amepre.2019.03.011","article-title":"Insurance reimbursements for routinely recommended adult vaccines in the private sector","volume":"57","author":"Tsai","year":"2019","journal-title":"Am J Prev Med"},{"issue":"6","key":"10.1016\/j.jval.2022.08.003_bib40","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/pds.4184","article-title":"Burden of hospitalizations related to adverse drug events in the USA: a retrospective analysis from large inpatient database","volume":"26","author":"Poudel","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"10.1016\/j.jval.2022.08.003_bib41","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jval.2022.08.003_bib42","series-title":"Cost-Effectiveness in Health and Medicine","year":"2016"},{"issue":"5","key":"10.1016\/j.jval.2022.08.003_bib43","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1503\/cmaj.061709","article-title":"Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection","volume":"177","author":"Brisson","year":"2007","journal-title":"CMAJ"},{"key":"10.1016\/j.jval.2022.08.003_bib45","author":"Linley"},{"issue":"11","key":"10.1016\/j.jval.2022.08.003_bib46","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/cid\/civ183","article-title":"Ten-year survival by race\/ethnicity and sex among treated, HIV-infected adults in the United States","volume":"60","author":"Lesko","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jval.2022.08.003_bib47","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1158\/1055-9965.EPI-12-0815","article-title":"The epidemiology of herpes zoster in patients with newly diagnosed cancer","volume":"22","author":"Habel","year":"2013","journal-title":"Cancer Epidemiol Prev Biomark"},{"issue":"40","key":"10.1016\/j.jval.2022.08.003_bib48","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.15585\/mmwr.mm6740a4","article-title":"Vaccination coverage among children aged 19-35 months\u2014United States, 2017","volume":"67","author":"Hill","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.jval.2022.08.003_bib49","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/cid\/ciz769","article-title":"Incidence of hospitalizations and emergency department visits for herpes zoster in immunocompromised and immunocompetent adults in Ontario, Canada, 2002-2016","volume":"71","author":"Buchan","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jval.2022.08.003_bib50","doi-asserted-by":"crossref","first-page":"ofw067","DOI":"10.1093\/ofid\/ofw067","article-title":"Cost of herpes zoster in patients with selected immune-compromised conditions in the United States","volume":"3","author":"Li","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"22","key":"10.1016\/j.jval.2022.08.003_bib52","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jval.2022.08.003_bib53","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40273-018-0735-1","article-title":"Cost-effectiveness of herpes zoster vaccination: a systematic review","volume":"37","author":"Chiyaka","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"10.1016\/j.jval.2022.08.003_bib54","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/cid\/ciab629","article-title":"The adjuvanted recombinant zoster vaccine confers long-term protection against herpes zoster: interim results of an extension study of the pivotal phase 3 clinical trials ZOE-50 and ZOE-70","volume":"74","author":"Boutry","year":"2022","journal-title":"Clin Infect Dis"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830152202143X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830152202143X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:31:48Z","timestamp":1761096708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109830152202143X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S109830152202143X"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2022.08.003","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness Analysis of Vaccination With Recombinant Zoster Vaccine Among Hematopoietic Cell Transplant Recipients and Persons With Other Immunocompromising Conditions Aged 19 to 49 Years","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2022.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}